Prevail Innovative Wealth Advisors LLC Raises Holdings in Merck & Co., Inc. $MRK

Prevail Innovative Wealth Advisors LLC raised its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 45.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 29,458 shares of the company's stock after purchasing an additional 9,145 shares during the period. Prevail Innovative Wealth Advisors LLC's holdings in Merck & Co., Inc. were worth $3,785,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Somerset Trust Co raised its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company's stock valued at $1,118,000 after buying an additional 81 shares during the last quarter. Stonebridge Financial Group LLC boosted its position in Merck & Co., Inc. by 0.9% during the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock worth $1,124,000 after acquiring an additional 81 shares during the last quarter. Lederer & Associates Investment Counsel CA grew its stake in Merck & Co., Inc. by 0.9% during the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company's stock valued at $1,234,000 after acquiring an additional 84 shares in the last quarter. Pine Haven Investment Counsel Inc grew its stake in Merck & Co., Inc. by 0.6% during the 2nd quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company's stock valued at $1,834,000 after acquiring an additional 86 shares in the last quarter. Finally, Chesapeake Wealth Management raised its holdings in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company's stock valued at $1,552,000 after acquiring an additional 87 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of research reports. BMO Capital Markets raised their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. CICC Research initiated coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an "outperform" rating and a $138.00 price target for the company. Argus increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday. Cantor Fitzgerald reiterated a "neutral" rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Finally, Barclays boosted their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and an average target price of $135.50.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $133.10 on Thursday. The firm has a 50 day simple moving average of $124.94 and a 200-day simple moving average of $119.64. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock has a market cap of $328.38 billion, a price-to-earnings ratio of 106.48, a price-to-earnings-growth ratio of 5.62 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the previous year, the company earned $2.13 EPS. The business's revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts expect that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio is currently 272.00%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst sentiment improved: Daiwa Securities upgraded Merck to “outperform” and set a $143 price target, while Argus raised its target to $145 and maintained a “buy” rating. These targets imply additional upside from recent trading levels. Daiwa Securities upgrade
• Positive Sentiment: RSV expansion opportunity: The FDA and European Medicines Agency accepted supplemental applications for broader use of ENFLONSIA to prevent RSV in vulnerable young children. The regulatory reviews could expand Merck’s growth beyond oncology and help diversify the portfolio ahead of Keytruda’s future patent expirations. Merck RSV regulatory review article
• Positive Sentiment: Estimates edged higher: Erste Group raised its FY2026 earnings forecast for Merck to $2.75 per share from $2.70, broadly aligning with the $2.76 consensus estimate. The company also recently exceeded quarterly revenue and adjusted earnings expectations, reporting $16.61 billion in revenue.
• Positive Sentiment: Core business remains solid: Keytruda, oncology and animal health supported quarterly growth, while the company continues investing in its pipeline. Merck also declared its regular $0.85 quarterly dividend, equivalent to a $3.40 annualized payout.
• Neutral Sentiment: Vaccine-policy uncertainty: Reports that the administration may seek to split the MMR vaccine into separate shots could create headlines around the broader vaccine market, but experts say the proposal lacks scientific support and is unlikely to advance. MMR vaccine policy article
• Negative Sentiment: Repeated insider selling: EVP Richard R. Deluca sold roughly 45,000 shares across transactions from August 6 through August 12 for approximately $6.7 million. Although he retained a substantial position, the sales may weigh modestly on sentiment.
• Negative Sentiment: Longer-term risks persist: Analysts continue to flag falling estimates, a high valuation and upcoming patent expirations, particularly the eventual loss of Keytruda exclusivity. These issues could limit upside unless Merck’s pipeline and newer products offset the expected revenue pressure.

Insiders Place Their Bets

In related news, EVP Richard R. Deluca sold 20,784 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the sale, the executive vice president directly owned 134,703 shares of the company's stock, valued at approximately $17,569,312.29. This trade represents a 13.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 137,923 shares of company stock valued at $17,908,943. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source